<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated">
      <PMID Version="1">34033068</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>01</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>01</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2520-8721</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>20</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Sep</Month>
            </PubDate>
          </JournalIssue>
          <Title>Hormones (Athens, Greece)</Title>
          <ISOAbbreviation>Hormones (Athens)</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Higher ovulation rate with letrozole as compared with clomiphene citrate in infertile women with polycystic ovary syndrome: a systematic review and meta-analysis.</ArticleTitle>
        <Pagination>
          <StartPage>449</StartPage>
          <EndPage>461</EndPage>
          <MedlinePgn>449-461</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s42000-021-00289-z</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Polycystic ovary syndrome (PCOS) is a common cause of anovulatory infertility. According to the latest guidelines, letrozole should be considered as the first-line pharmacological treatment for women with WHO Group II anovulation or PCOS. However, the use of letrozole as an ovulation induction agent is not FDA or EMA approved, and its use is "off-label." The main concern with respect to letrozole regards its potential teratogenic effect on the fetus.</AbstractText>
          <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">To determine whether the probability of ovulation is higher with letrozole as compared to clomiphene citrate (CC) in anovulatory women with PCOS.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">Randomized controlled trials (RCTs) comparing letrozole versus CC used for ovulation induction in infertile women with PCOS followed by timed intercourse (TI) or intrauterine insemination (IUI) were included in this meta-analysis. Primary outcome was ovulation. Secondary outcomes were live birth, clinical pregnancy, miscarriage, multiple pregnancy, and congenital anomalies. Subgroup analysis included patients who received letrozole or CC as first-line treatment, and patients with PCOS diagnosed according to the Rotterdam criteria.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">Twenty-six RCTs published between 2006 and 2019, involving 4168 patients who underwent 8310 cycles of ovulation induction, were included. The probability of ovulation was significantly higher in letrozole as compared to CC cycles (RR: 1.148, 95% CI: 1.077 to 1.223, 3017 women, 19 trials, I<sup>2</sup>: 47.7%, low-quality evidence).</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">A higher probability of ovulation is expected in infertile patients with PCOS treated with letrozole as compared to CC. The higher ovulation rate might have contributed to the higher clinical pregnancy and live birth rate. This finding is also true for patients who were administered letrozole as first-line treatment.</AbstractText>
          <AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">CRD42019125166.</AbstractText>
          <CopyrightInformation>© 2021. Hellenic Endocrine Society.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Tsiami</LastName>
            <ForeName>Alexandra P</ForeName>
            <Initials>AP</Initials>
            <AffiliationInfo>
              <Affiliation>National and Kapodistrian University of Athens, Irakleitou 1, 50132, Kozani, Greece. alexandratsiami@hotmail.gr.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Goulis</LastName>
            <ForeName>Dimitrios G</ForeName>
            <Initials>DG</Initials>
            <AffiliationInfo>
              <Affiliation>Unit of Reproductive Endocrinology, 1st Department of Obstetrics and Gynecology, Papageorgiou General Hospital, Aristotle University of Thessaloniki, 54629, Thessaloniki, Greece.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sotiriadis</LastName>
            <ForeName>Alexandros I</ForeName>
            <Initials>AI</Initials>
            <AffiliationInfo>
              <Affiliation>2nd Department of Obstetrics and Gynecology, Faculty of Medicine, Hippokration General Hospital, Aristotle University of Thessaloniki, 54642, Thessaloniki, Greece.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kolibianakis</LastName>
            <ForeName>Efstratios M</ForeName>
            <Initials>EM</Initials>
            <AffiliationInfo>
              <Affiliation>Unit of Human Reproduction, 1st Department of Obstetrics and Gynecology, Aristotle University of Thessaloniki Papageorgiou General Hospital, 54629, Thessaloniki, Greece.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D017418">Meta-Analysis</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
          <PublicationType UI="D000078182">Systematic Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>05</Month>
          <Day>25</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Switzerland</Country>
        <MedlineTA>Hormones (Athens)</MedlineTA>
        <NlmUniqueID>101142469</NlmUniqueID>
        <ISSNLinking>1109-3099</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D005300">Fertility Agents, Female</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>1HRS458QU2</RegistryNumber>
          <NameOfSubstance UI="D002996">Clomiphene</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>7LKK855W8I</RegistryNumber>
          <NameOfSubstance UI="D000077289">Letrozole</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D002996" MajorTopicYN="N">Clomiphene</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005300" MajorTopicYN="N">Fertility Agents, Female</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007247" MajorTopicYN="Y">Infertility, Female</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077289" MajorTopicYN="N">Letrozole</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010062" MajorTopicYN="Y">Ovulation Induction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011085" MajorTopicYN="Y">Polycystic Ovary Syndrome</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Clomiphene citrate</Keyword>
        <Keyword MajorTopicYN="N">Letrozole</Keyword>
        <Keyword MajorTopicYN="N">Meta-analyses</Keyword>
        <Keyword MajorTopicYN="N">Ovulation</Keyword>
        <Keyword MajorTopicYN="N">Ovulation induction therapy</Keyword>
        <Keyword MajorTopicYN="N">PCOS</Keyword>
        <Keyword MajorTopicYN="N">Systematic review</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>11</Month>
          <Day>15</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>29</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>3</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>25</Day>
          <Hour>14</Hour>
          <Minute>6</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34033068</ArticleId>
        <ArticleId IdType="doi">10.1007/s42000-021-00289-z</ArticleId>
        <ArticleId IdType="pii">10.1007/s42000-021-00289-z</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Ehrmann DA (2005) Polycystic ovary syndrome. N Engl J Med 352(12):1223–1236. https://doi.org/10.1056/NEJMra041536</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMra041536</ArticleId>
            <ArticleId IdType="pubmed">15788499</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO (2004) The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 89(6):2745–2749. https://doi.org/10.1210/jc.2003-032046</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/jc.2003-032046</ArticleId>
            <ArticleId IdType="pubmed">15181052</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bozdag G, Mumusoglu S, Zengin D, Karabulut E, Yildiz BO (2016) The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod 31(12):2841–2855. https://doi.org/10.1093/humrep/dew218</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/humrep/dew218</ArticleId>
            <ArticleId IdType="pubmed">27664216</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group (2008) Consensus on infertility treatment related to polycystic ovary syndrome [published correction appears in Hum Reprod. 2008 Jun;23(6):1474]. Hum Reprod 23(3):462–477. https://doi.org/10.1093/humrep/dem426</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/humrep/dem426</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>ESHRE Capri Workshop Group (2012) Health and fertility in World Health Organization group 2 anovulatory women. Hum Reprod Update 18(5):586–599. https://doi.org/10.1093/humupd/dms019</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/humupd/dms019</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Balen AH, Morley LC, Misso M et al (2016) The management of anovulatory infertility in women with polycystic ovary syndrome: an analysis of the evidence to support the development of global WHO guidance. Hum Reprod Update 22(6):687–708. https://doi.org/10.1093/humupd/dmw025</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/humupd/dmw025</ArticleId>
            <ArticleId IdType="pubmed">27511809</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Melo AS, Ferriani RA, Navarro PA (2015) Treatment of infertility in women with polycystic ovary syndrome: approach to clinical practice. Clinics (Sao Paulo) 70(11):765–769. https://doi.org/10.6061/clinics/2015(11)09</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.6061/clinics/2015(11)09</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>O’Flynn N (2014) Assessment and treatment for people with fertility problems: NICE guideline. Br J Gen Pract 64(618):50–51. https://doi.org/10.3399/bjgp14X676609</Citation>
        </Reference>
        <Reference>
          <Citation>Moghetti P, Carmina E, De Leo V et al (2015) How to manage the reproductive issues of PCOS: a 2015 integrated endocrinological and gynecological consensus statement of the Italian Society of Endocrinology. J Endocrinol Invest 38(9):1025–1037. https://doi.org/10.1007/s40618-015-0274-y</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s40618-015-0274-y</ArticleId>
            <ArticleId IdType="pubmed">25835559</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Legro RS, Arslanian SA, Ehrmann DA et al (2013) Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 98(12):4565–4592. https://doi.org/10.1210/jc.2013-2350</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/jc.2013-2350</ArticleId>
            <ArticleId IdType="pubmed">24151290</ArticleId>
            <ArticleId IdType="pmc">5399492</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Teede HJ, Norman RJ, Garad RM (2019) A new evidence‐based guideline for assessment and management of polycystic ovary syndrome. Med J Aust 210(6): https://doi.org/10.5694/mja2.50053</Citation>
        </Reference>
        <Reference>
          <Citation>International evidence based guidelines for the assessment and management of polycystic ovary syndrome 2018. Australlian Clinical Practice Guidelines</Citation>
        </Reference>
        <Reference>
          <Citation>Homburg R (2010) Choices in the treatment of anovulatory PCOS. Current management of polycystic ovary syndrome. Edited by Adam Balen, Steve Franks and Roy Homburg. Proceedings of 59th RCOG Study Group, RCOG Press, London Cambridge University Press; pp 143–152. https://doi.org/10.1017/CBO9781107478343</Citation>
        </Reference>
        <Reference>
          <Citation>Homburg R (2005) Clomiphene citrate–end of an era? A mini-review. Hum Reprod 20(8):2043–2051. https://doi.org/10.1093/humrep/dei042</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/humrep/dei042</ArticleId>
            <ArticleId IdType="pubmed">15878925</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Messinis IE (2005) Ovulation induction: a mini review. Hum Reprod 20(10):2688–2697. https://doi.org/10.1093/humrep/dei128</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/humrep/dei128</ArticleId>
            <ArticleId IdType="pubmed">16006478</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nakamura Y, Ono M, Yoshida Y, Sugino N, Ueda K, Kato H (1997) Effects of clomiphene citrate on the endometrial thickness and echogenic pattern of the endometrium. Fertil Steril 67(2):256–260. https://doi.org/10.1016/S0015-0282(97)81907-3</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0015-0282(97)81907-3</ArticleId>
            <ArticleId IdType="pubmed">9022599</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Randall JM, Templeton A (1991) Cervical mucus score and in vitro sperm mucus interaction in spontaneous and clomiphene citrate cycles. Fertil Steril. 56(3):465–468. https://doi.org/10.1016/s0015-0282(16)54541-5</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/s0015-0282(16)54541-5</ArticleId>
            <ArticleId IdType="pubmed">1894023</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hussein Z, Al-Obaidi MT, AL-Saadi WI, Selman MO (2017) Comparison of the effect of clomiphene citrate and letrozole on the endometrial parameters of PCOS women. J Pharm Sci Res 9(11):2291–2295</Citation>
        </Reference>
        <Reference>
          <Citation>Kousta E, White DM, Franks S (1997) Modern use of clomiphene citrate in induction of ovulation. Hum Reprod Update. 3(4):359–365. https://doi.org/10.1093/humupd/3.4.359</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/humupd/3.4.359</ArticleId>
            <ArticleId IdType="pubmed">9459281</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brown J, Farquhar C, Beck J, Boothroyd C, Hughes E (2009) Clomiphene and anti-oestrogens for ovulation induction in PCOS. Cochrane Database Syst Rev (4):CD002249. https://doi.org/10.1002/14651858.CD002249.pub4. Published 2009 Oct 7</Citation>
        </Reference>
        <Reference>
          <Citation>Mitwally MF, Casper RF (2001) Use of an aromatase inhibitor for induction of ovulation in patients with an inadequate response to clomiphene citrate. Fertil Steril 75(2):305–309. https://doi.org/10.1016/s0015-0282(00)01705-2</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/s0015-0282(00)01705-2</ArticleId>
            <ArticleId IdType="pubmed">11172831</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Amer SA, Smith J, Mahran A, Fox P, Fakis A (2017) Double-blind randomized controlled trial of letrozole versus clomiphene citrate in subfertile women with polycystic ovarian syndrome. Hum Reprod 32(8):1631–1638. https://doi.org/10.1093/humrep/dex227</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/humrep/dex227</ArticleId>
            <ArticleId IdType="pubmed">28854590</ArticleId>
            <ArticleId IdType="pmc">5850470</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Legro RS, Brzyski RG, Diamond MP et al (2014) Letrozole versus clomiphene for infertility in the polycystic ovary syndrome [published correction appears in N Engl J Med. 2014;317(15):1465]. N Engl J Med. 371(2):119–129. https://doi.org/10.1056/NEJMoa1313517</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1313517</ArticleId>
            <ArticleId IdType="pubmed">25006718</ArticleId>
            <ArticleId IdType="pmc">4175743</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Birch Petersen K, Pedersen NG, Pedersen AT, Lauritsen MP, la Cour FN (2016) Mono-ovulation in women with polycystic ovary syndrome: a clinical review on ovulation induction. Reprod Biomed Online 32(6):563–583. https://doi.org/10.1016/j.rbmo.2016.03.006</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.rbmo.2016.03.006</ArticleId>
            <ArticleId IdType="pubmed">27151490</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Usadi RS, Merriam KS (2015) On-label and off-label drug use in the treatment of female infertility. Fertil Steril 103(3):583–594. https://doi.org/10.1016/j.fertnstert.2015.01.011</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.fertnstert.2015.01.011</ArticleId>
            <ArticleId IdType="pubmed">25660647</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Palomba S (2015) Aromatase inhibitors for ovulation induction. J Clin Endocrinol Metab 100(5):1742–1747. https://doi.org/10.1210/jc.2014-4235</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/jc.2014-4235</ArticleId>
            <ArticleId IdType="pubmed">25710566</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Biljan MM, Hemmings R, Brassard N (2005) The outcome of 150 babies following the treatment with letrozole or letrozole and gonadotropins. Fertil Sreril 84(Suppl1):S95. https://doi.org/10.1016/j.fertnstert.2005.07.230</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.fertnstert.2005.07.230</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Forman R, Gill S, Moretti M, Tulandi T, Koren G, Casper R (2007) Fetal safety of letrozole and clomiphene citrate for ovulation induction. J Obstet Gynaecol Can 29(8):668–671. https://doi.org/10.1016/s1701-2163(16)32551-8</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/s1701-2163(16)32551-8</ArticleId>
            <ArticleId IdType="pubmed">17714621</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tulandi T, Martin J, Al-Fadhli R et al (2006) Congenital malformations among 911 newborns conceived after infertility treatment with letrozole or clomiphene citrate. Fertil Steril 85(6):1761–1765. https://doi.org/10.1016/j.fertnstert.2006.03.014</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.fertnstert.2006.03.014</ArticleId>
            <ArticleId IdType="pubmed">16650422</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sharma S, Ghosh S, Singh S, et al (2014) Congenital malformations among babies born following letrozole or clomiphene for infertility treatment. PLoS One 9(10):e108219. Published 2014 Oct 1. https://doi.org/10.1371/journal.pone.0108219</Citation>
        </Reference>
        <Reference>
          <Citation>Roque M, Tostes AC, Valle M, Sampaio M, Geber S (2015) Letrozole versus clomiphene citrate in polycystic ovary syndrome: systematic review and meta-analysis. Gynecol Endocrinol 31(12):917–921. https://doi.org/10.3109/09513590.2015.1096337</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3109/09513590.2015.1096337</ArticleId>
            <ArticleId IdType="pubmed">26479460</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gadalla MA, Huang S, Wang R, Norman RJ, Abdullah SA, El Saman AM, Ismail AM, van Wely M, Mol BWJ (2018) Effect of clomiphene citrate on endometrial thickness, ovulation, pregnancy and live birth in anovulatory women: systematic review and meta-analysis. Ultrasound Obstet Gynecol 51(1):64–76. https://doi.org/10.1002/uog.18933</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/uog.18933</ArticleId>
            <ArticleId IdType="pubmed">29055102</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Franik S, Eltrop SM, Kremer JA, Kiesel L, Farquhar C (2018) Aromatase inhibitors (letrozole) for subfertile women with polycystic ovary syndrome. Cochrane Database Syst Rev 5. https://doi.org/10.1002/14651858.CD010287</Citation>
        </Reference>
        <Reference>
          <Citation>Misso ML, Wong JL, Teede HJ, Hart R, Rombauts L, Melder AM, Norman RJ, Costello MF (2012) Aromatase inhibitors for PCOS: a systematic review and meta-analysis. Human Reprod Update 18(3):301–312. https://doi.org/10.1093/humupd/dms003</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/humupd/dms003</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 2009; https://doi.org/10.1016/j.jclinepi.2009.06.005</Citation>
        </Reference>
        <Reference>
          <Citation>Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng H-Y, Corbett MS, Eldridge SM, Hernán MA, Hopewell S, Hróbjartsson A, Junqueira DR, Jüni P, Kirkham JJ, Lasserson T, Li T, McAleenan A, Reeves BC, Shepperd S, Shrier I, Stewart LA, Tilling K, White IR, Whiting PF, Higgins JPT (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:l4898</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bmj.l4898</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McMaster University (2015) (developed by Evidence Prime, Inc.). GRADEpro GDT: GRADEpro Guideline Development Tool [Software].  https://gradepro.org/ . Accessed 23 Jan 2021</Citation>
        </Reference>
        <Reference>
          <Citation>OpenMetaAnalyst_win 8 Software</Citation>
        </Reference>
        <Reference>
          <Citation>Borenstein M, Hedges L, Higgins J, Rothstein H (2013) Biostat, Englewood, NJ Comprehensive Meta-Analysis Version 3</Citation>
        </Reference>
        <Reference>
          <Citation>McGuinness, LA, Higgins, JPT (2020) Risk-of-bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments. Res Syn Meth. 1-7. https://doi.org/10.1002/jrsm.1411</Citation>
        </Reference>
        <Reference>
          <Citation>Atay V, Cam C, Muhcu M, Cam M, Karateke A (2006) Comparison of letrozole and clomiphene citrate in women with polycystic ovaries undergoing ovarian stimulation. J Int Med Res 34(1):73–76. https://doi.org/10.1177/147323000603400109</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/147323000603400109</ArticleId>
            <ArticleId IdType="pubmed">16604826</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aygen EM, Guzel Z, Ozgun T, Atakul T, Sahin Y (2007) The use of letrozole for ovulation induction in infertile women with polycystic ovarian syndrome. Erciyes Med Journal 29:195–200</Citation>
        </Reference>
        <Reference>
          <Citation>Abd EL Fatah AGK, Abd El Salam Wafa Y, Labib MM (2017) Role of letrozole versus clomiphene citrate in induction of ovulation in patients with polycystic ovarian syndrome. J Gynecol Reprod Med 1</Citation>
        </Reference>
        <Reference>
          <Citation>Badawy A, Abdel Aal I, Abulatta M (2009) Clomiphene citrate or letrozole for ovulation induction in women with polycystic ovarian syndrome: a prospective randomized trial. Fertil Steril 92(3):849–852. https://doi.org/10.1016/j.fertnstert.2007.02.062</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.fertnstert.2007.02.062</ArticleId>
            <ArticleId IdType="pubmed">17582406</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bayar U, Basaran M, Kiran S, Coskun A, Gezer S (2006) Use of an aromatase inhibitor in patients with polycystic ovary syndrome: a prospective randomized trial. Fertil Steril 86(5):1447–1451. https://doi.org/10.1016/j.fertnstert.2006.04.026</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.fertnstert.2006.04.026</ArticleId>
            <ArticleId IdType="pubmed">17070196</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Begum MR, Ferdous J, Begum A, Quadir E (2009) Comparison of efficacy of aromatase inhibitor and clomiphene citrate in induction of ovulation in polycystic ovarian syndrome. Fertil Steril 92(3):853–857. https://doi.org/10.1016/j.fertnstert.2007.08.044</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.fertnstert.2007.08.044</ArticleId>
            <ArticleId IdType="pubmed">18177867</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Behnoud N, Farzaneh F, Ershadi S (2019) the effect of clomiphene citrate versus letrozole on pregnancy rate in women with polycystic ovary syndrome: a randomized clinical trial. Crescent J Med Biol Sci 6(3):335–340</Citation>
        </Reference>
        <Reference>
          <Citation>Chen Z, Zhang M, Qiao Y, Yang J (2016) Effects of letrozole in combination with low-dose intramuscular injection of human menopausal gonadotropin on ovulation and pregnancy of 156 patients with polycystic ovary syndrome. Pak J Med Sci 32(6):1434–1438. https://doi.org/10.12669/pjms.326.11391</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.12669/pjms.326.11391</ArticleId>
            <ArticleId IdType="pubmed">28083040</ArticleId>
            <ArticleId IdType="pmc">5216296</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dehbashi S, Kazerooni T, Robati M, Alborzi S, Parsanezhad ME, Shadman A (2009) Comparison of the effects of letrozole and clomiphene citrate on ovulation and pregnancy rate in patients with polycystic ovary syndrome. Iran J Med Sci 34:23–28</Citation>
        </Reference>
        <Reference>
          <Citation>Ghahiri A, Mogharehabed N, Mamourian M (2016) Letrozole as the first-line treatment of infertile women with poly cystic ovarian syndrome (PCOS) compared with clomiphene citrate: A clinical trial. Adv Biomed Res 5:6. https://doi.org/10.4103/2277-9175.175237</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4103/2277-9175.175237</ArticleId>
            <ArticleId IdType="pubmed">26962508</ArticleId>
            <ArticleId IdType="pmc">4770610</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu C, Feng G, Huang W et al (2017) Comparison of clomiphene citrate and letrozole for ovulation induction in women with polycystic ovary syndrome: a prospective randomized trial. Gynecol Endocrinol 33(11):872–876. https://doi.org/10.1080/09513590.2017.1332174</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/09513590.2017.1332174</ArticleId>
            <ArticleId IdType="pubmed">28557652</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moussa AA, Torky H, Dief O, Elwahed AA, Senna HA (2016) The effect of clomiphene citrate versus tamoxifen versus letrozol on endometrial thickness and blood flow in ovulation induction in women with polycystic ovaries. Acta Medica International 3(2):88–92. https://doi.org/10.5530/ami.2016.2.19</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5530/ami.2016.2.19</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nahid L, Sirous K (2012) Comparison of the effects of letrozole and clomiphene citrate for ovulation induction in infertile women with polycystic ovary syndrome. Minerva Ginecol 64(3):253–258</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22635021</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nazik H, Kumtepe Y (2012) Comparison of efficacy of letrozole and clomiphene citrate in ovulation induction for women with polycystic ovarian syndrome. Health Med 6(3):879–883</Citation>
        </Reference>
        <Reference>
          <Citation>Nik Hussain ΝΚ, Ismail Μ, Zain ΜΜ, Yeu PC, Wan Mohammad (2013) Randomized controlled trial of letrozole versus clomiphene citrate for induction of ovulation in polycystic ovarian syndrome (PCOS) a Malaysian experience. Open J Obstet Gynecol, 3:11–17. https://doi.org/10.4236/ojog.2013.35A2003</Citation>
        </Reference>
        <Reference>
          <Citation>Ray PB, Ray A, Chakraborti PS (2012) Comparison of efficacy of letrozole and clomiphene citrate in ovulation induction in Indian women with polycystic ovarian syndrome. Arch Gynecol Obstet 285(3):873–877. https://doi.org/10.1007/s00404-011-2091-7</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00404-011-2091-7</ArticleId>
            <ArticleId IdType="pubmed">21984038</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roy KK, Baruah J, Singla S et al (2012) A prospective randomized trial comparing the efficacy of Letrozole and Clomiphene citrate in induction of ovulation in polycystic ovarian syndrome. J Hum Reprod Sci 5(1):20–25. https://doi.org/10.4103/0974-1208.97789</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4103/0974-1208.97789</ArticleId>
            <ArticleId IdType="pubmed">22870010</ArticleId>
            <ArticleId IdType="pmc">3409915</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Selim MF, Borg TF (2012) Letrozole and clomiphene citrate effect on endometrial and subendometrial vascularity in treating infertility in women with polycystic ovary syndrome. J Gynecol Surg 28(6):405–410. https://doi.org/10.1089/gyn.2012.0033</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/gyn.2012.0033</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sharief M, Nafee NR (2015) Comparison of letrazole and clomiphene citrate in women with polycystic ovaries undergoing ovarian stimulation. J Pak Med Assoc 65(11):1149–1152</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26564281</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sheikh-El-Arab Elsedeek M, Elmaghraby HAH (2011) Predictors and characteristics of letrozole induced ovulation in comparison with clomiphene induced ovulation in anovulatory PCOS women. Middle East Fertil Soc J 16:125–130. https://doi.org/10.1016/j.mefs.2010.11.004</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.mefs.2010.11.004</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang L, Wen X, Lv S, Zhao J, Yang T, Yang X (2019) Comparison of endometrial receptivity of clomiphene citrate versus letrozole in women with polycystic ovary syndrome: a randomized controlled study. Gynecol Endocrinol 35(10):862–865. https://doi.org/10.1080/09513590.2019.1612358</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/09513590.2019.1612358</ArticleId>
            <ArticleId IdType="pubmed">31081404</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hendawy SF, Samaha HE, Elkholy MF (2011) Letrozole versus clomiphene citrate for induction of ovulation in patients with polycystic ovarian syndrome undergoing intrauterine insemination. Clin Med Insights Reprod Health 5:11–16. https://doi.org/10.4137/CMRH.S6598</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4137/CMRH.S6598</ArticleId>
            <ArticleId IdType="pubmed">24453507</ArticleId>
            <ArticleId IdType="pmc">3888072</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kar S (2012) Clomiphene citrate or letrozole as first-line ovulation induction drug in infertile PCOS women: a prospective randomized trial. J Hum Reprod Sci 5(3):262–265. https://doi.org/10.4103/0974-1208.106338</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4103/0974-1208.106338</ArticleId>
            <ArticleId IdType="pubmed">23531705</ArticleId>
            <ArticleId IdType="pmc">3604833</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zeinalzadeh M, Basirat Z, Esmailpour M (2010) Efficacy of letrozole in ovulation induction compared to that of clomiphene citrate in patients with polycystic ovarian syndrome. J Reprod Med 55(1–2):36–40</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20337206</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>He D, Jiang F (2011) Meta-analysis of letrozole versus clomiphene citrate in polycystic ovary syndrome. Reprod Biomed Online 23(1):91–96. https://doi.org/10.1016/j.rbmo.2011.03.024</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.rbmo.2011.03.024</ArticleId>
            <ArticleId IdType="pubmed">21550852</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hu S, Yu Q, Wang Y, Wang M, Xia W, Zhu C (2018) Letrozole versus clomiphene citrate in polycystic ovary syndrome: a meta-analysis of randomized controlled trials. Arch Gynecol Obstet 297(5):1081–1088. https://doi.org/10.1007/s00404-018-4688-6</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00404-018-4688-6</ArticleId>
            <ArticleId IdType="pubmed">29392438</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Casper R, Mitwally M. Ovulation induction with Letrozole. UpToDate Nov 2020</Citation>
        </Reference>
        <Reference>
          <Citation>Tiboni GM (2004) Aromatase inhibitors and teratogenesis. Fertil Steril 81(4):1158–9; author reply 1159. https://doi.org/10.1016/j.fertnstert.2004.01.006</Citation>
        </Reference>
        <Reference>
          <Citation>AkbariSene A, Ghorbani S, Ashrafi M (2018) Comparison of the pregnancy outcomes and the incidence of fetal congenital abnormalities in infertile women treated with letrozole and clomiphene citrate. J Obstet Gynaecol Res 44(6):1036–1041. https://doi.org/10.1111/jog.13644</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/jog.13644</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tatsumi T, Jwa SC, Kuwahara A, Irahara M, Kubota T, Saito H (2017) No increased risk of major congenital anomalies or adverse pregnancy or neonatal outcomes following letrozole use in assisted reproductive technology. Hum Reprod 32(1):125–132. https://doi.org/10.1093/humrep/dew280</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/humrep/dew280</ArticleId>
            <ArticleId IdType="pubmed">27821708</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
